Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study - 05/10/20
, Seung Won Lee, MD, PhD c, ⁎
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
There is inconclusive and controversial evidence of the association between allergic diseases and the risk of adverse clinical outcomes of coronavirus disease 2019 (COVID-19).
Objective |
We sought to determine the association of allergic disorders with the likelihood of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result and with clinical outcomes of COVID-19 (admission to intensive care unit, administration of invasive ventilation, and death).
Methods |
A propensity-score–matched nationwide cohort study was performed in South Korea. Data obtained from the Health Insurance Review & Assessment Service of Korea from all adult patients (age, >20 years) who were tested for SARS-CoV-2 in South Korea between January 1, 2020, and May 15, 2020, were analyzed. The association of SARS-CoV-2 test positivity and allergic diseases in the entire cohort (n = 219,959) and the difference in clinical outcomes of COVID-19 were evaluated in patients with allergic diseases and SARS-CoV-2 positivity (n = 7,340).
Results |
In the entire cohort, patients who underwent SARS-CoV-2 testing were evaluated to ascertain whether asthma and allergic rhinitis were associated with an increased likelihood of SARS-CoV-2 test positivity. After propensity score matching, we found that asthma and allergic rhinitis were associated with worse clinical outcomes of COVID-19 in patients with SARS-CoV-2 test positivity. Patients with nonallergic asthma had a greater risk of SARS-CoV-2 test positivity and worse clinical outcomes of COVID-19 than patients with allergic asthma.
Conclusions |
In a Korean nationwide cohort, allergic rhinitis and asthma, especially nonallergic asthma, confers a greater risk of susceptibility to SARS-CoV-2 infection and severe clinical outcomes of COVID-19.
Le texte complet de cet article est disponible en PDF.Key words : COVID-19, asthma, allergic rhinitis, atopic dermatitis
Abbreviations used : aOR, COPD, COVID-19, ICD-10, ICU, SARS-CoV-2, SMD
Plan
| This work was supported by the National Research Foundation of Korea grant funded by the Korean government (grant no. NRF2019R1G1A109977912). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 4
P. 790-798 - octobre 2020 Retour au numéro
Article précédent
- Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities
- Zita-Rose Manjaly Thomas, Anne Leuppi-Taegtmeyer, Dagmar Jamiolkowski, Esther Steveling-Klein, Felicitas Bellutti-Enders, Kathrin Scherer Hofmeier, Karin Hartmann
- IL-6–based mortality risk model for hospitalized patients with COVID-19
- Rocio Laguna-Goya, Alberto Utrero-Rico, Paloma Talayero, Maria Lasa-Lazaro, Angel Ramirez-Fernandez, Laura Naranjo, Alejandro Segura-Tudela, Oscar Cabrera-Marante, Edgar Rodriguez de Frias, Rocio Garcia-Garcia, Mario Fernández-Ruiz, Jose Maria Aguado, Joaquin Martinez-Lopez, Elena Ana Lopez, Mercedes Catalan, Antonio Serrano, Estela Paz-Artal
Bienvenue sur EM-consulte, la référence des professionnels de santé.